Abstract | BACKGROUND: This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma. MATERIALS AND METHODS: Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) techniques. RESULTS: Forty patients with mean age 57.9±19.5 years were enrolled in this study. The most frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2/ neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case (2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the mean of Breslow thickness was 3.56±2.87 mm. The stage of the case that showed weakly positive staining (2+) in IHC was 4b. CONCLUSIONS: The amplification of HER2/neu biomarker was negative in patients with melanoma, using both CISH and IHC techniques.
|
Authors | Nasrin Shayanfar, Leila Bahari, Zahra Safaie-Naraghi, Kambiz Kamyab, Elmira Gheytanchi, Nima Rezaei |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 16
Issue 2
Pg. 421-5
( 2015)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 25684465
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(genetics, metabolism)
- Child
- Cross-Sectional Studies
- Female
- Follow-Up Studies
- Gene Amplification
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization
- Male
- Melanoma
(genetics, metabolism, pathology)
- Middle Aged
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2
(genetics, metabolism)
- Skin Neoplasms
(genetics, metabolism, pathology)
- Young Adult
|